ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Natural Substance Blocks Androgen Activity In Vitro

April 27, 2001

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens

October 6, 1978

Also in this 8-page issue: Amendment strips funding from two NIHM grants. NCI will commit $7 million to begin restructuring its clinical trials system, Institute director says.

July 1, 2005

NCI-Approved Clinical Trials Listed For January

January 28, 2005

New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again.

January 11, 2008